Prevention & lipidsResearch article
Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering
- Narrative review
Study context
- Population
- High-risk patients requiring low-density lipoprotein cholesterol (LDL-C) lowering for prevention and treatment of atherosclerotic cardiovascular disease (ASCVD)
Main finding
As reported in the abstract
Challenges of current LDL-C lowering therapies and LDL-C target attainment (narrative review)
- Many high-risk patients do not achieve guideline-recommended LDL-C targets
- Low adherence to statin therapy, even after an acute coronary event
- Ezetimibe and PCSK9 monoclonal antibodies remain underutilized
- Inclisiran (small-interfering RNA (siRNA) targeting PCSK9 mRNA) available for clinical use though CV outcomes data are lacking
Original publication
Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering. Eur J Prev Cardiol. Published 5 March 2025. doi:10.1093/eurjpc/zwaf123
Summarised from the published abstract; every number is checked against it